Faculty Bibliography

Patients with complex chronic diseases usually must make multiple lifestyle changes to limit and manage their conditions. Numerous studies have shown that education alone is insufficient for engaging people in lifestyle behavior change, and that theory-based behavioral approaches also are necessary. However, even the most motivated individual may have difficulty with making lifestyle changes because of the information complexity associated with multiple behavior changes. The goal of the current Healthy Hearts and Kidneys study was to evaluate, different mobile health (mHealth)-delivered intervention approaches for engaging individuals with type 2 diabetes (T2D) and concurrent chronic kidney disease (CKD) in behavior changes. Participants were randomized to 1 of 4 groups, receiving: (1) a behavioral counseling, (2) technology-based self-monitoring to reduce information complexity, (3) combined behavioral counseling and technology-based self-monitoring, or (4) baseline advice. We will determine the impact of randomization assignment on weight loss success and 24-hour urinary excretion of sodium and phosphorus. With this report we describe the study design, methods, and approaches used to assure information security for this ongoing clinical trial. Clinical Trials.gov Identifier: NCT02276742.

BACKGROUND: Insulin resistance and endothelial dysfunction share a reciprocal relationship that links the metabolic and cardiovascular sequelae of obesity. We characterized the brachial artery reactivity testing (BART) and carotid artery-intima media thickness (CIMT) in adolescents categorized as obese insulin resistant (OIR) and obese not insulin resistant (ONIR). Lipoprotein particle (p) analysis and inflammatory cytokines in OIR and ONIR groups were also analyzed. METHODS: Obese adolescents (n=40; mean body mass index [BMI] 35.6) were categorized as ONIR and OIR based on their homeostatic model assessment of insulin resistance (HOMA-IR) calculation ( than 3.4). Ultrasound measured conduit arterial function BART, microvascular function (post-ischemic hyperemia) and conduit artery structure CIMT. RESULTS: BART did not differ according to IR status (mean+/-SD: 7.0+/-4.3% vs. 5.9+/-3.4% in ONIR and OIR, respectively, p=0.3, but post-ischemic hyperemia was significantly greater in the ONIR group (4.5+/-2.2 vs. 3.5+/-3, p=0.04). Atherogenic lipoprotein particles; large VLDL particles and small LDL particles were higher in the OIR compared to ONIR group. CONCLUSIONS: OIR adolescents demonstrate an inflamed atherogenic milieu compared to the ONIR adolescents. Microvascular function, but not conduit vessel structure or function, was impaired in association with IR.

PURPOSE: Driveline exit site (DLES) management following left ventricular assist device implantation is important for preventing driveline infection (DLI). While chlorhexidine gluconate (CHG) is generally recommended for DLES antisepsis, CHG intolerance can develop, resulting in a need for alternative antiseptics. We reviewed our institutional experience with DLES antisepsis methods in HeartMate II patients, comparing outcomes of patients with and without CHG intolerance. METHODS: Between October 2011 and March 2016, 44 patients underwent primary HeartMate II implantation. CHG was used for DLES antisepsis and povidone-iodine (PVP-I) was used in patients with CHG intolerance. DLI was defined by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) criteria. RESULTS: Of 44 patients, 37 (84%) received CHG and 7 (16%) received PVP-I antisepsis due to CHG intolerance. Five patients (11.4%) developed a DLI, with an event per patient-year rate of 0.07. Median length of support was 521 days (interquartile range 202-881 days). Characteristics were similar between patients with and without DLI. However, a larger proportion of patients with DLI had CHG intolerance compared to patients without DLI (60.0% vs. 10.3%, p:0.05). Causative organisms were Staphylococcus aureus in CHG-intolerant patients and Stenotrophomonas and Acinetobacter in CHG-tolerant patients. Kaplan-Meier method and log-rank test demonstrated decreased infection-free days in patients using PVP-I rather than CHG (p:0.01). CONCLUSIONS: While the etiology of DLI is multifactorial, CHG intolerance appears to be a risk factor. Our findings highlight the need for larger studies comparing the efficacy of antiseptics for DLES care, particularly for patients with CHG contraindications.

OBJECTIVES: To determine the relationship between caregiver status and outcomes after durable left ventricular assist device (LVAD) implantation. BACKGROUND: The absence of a caregiver is a relative contraindication to durable LVAD support. METHODS: Forty-three patients that underwent primary LVAD implantation were divided into three groups: those with caregivers that retained their roles for the duration of LVAD support (CG group), those with caregivers that resigned their roles (CG-QUIT group), and those implanted without an assigned caregiver (No-CG group). Group-specific characteristics and post-implant outcomes were compared. RESULTS: In the CG-QUIT group, caregivers did not live in the same home (0.0% vs. 80.6% of CG group) and none were spouses (0.0% vs. 64.5% for CG group). Thirty-day readmission rate was highest in the CG-QUIT group (83.3% vs. 25.8% in CG group and 16.7% in No-CG group). CONCLUSIONS: Caregiver relationships were more likely to be maintained for the duration of LVAD support when the caregiver was a spouse and resided in the same home as the patient. Carefully selected patients implanted without a designated caregiver had comparable outcomes to those who retained their original caregiver.